CA2211324C - Recombinant human alpha-fetoprotein and uses thereof - Google Patents

Recombinant human alpha-fetoprotein and uses thereof Download PDF

Info

Publication number
CA2211324C
CA2211324C CA2211324A CA2211324A CA2211324C CA 2211324 C CA2211324 C CA 2211324C CA 2211324 A CA2211324 A CA 2211324A CA 2211324 A CA2211324 A CA 2211324A CA 2211324 C CA2211324 C CA 2211324C
Authority
CA
Canada
Prior art keywords
rhuafp
medicament
seq
amino acids
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2211324A
Other languages
English (en)
French (fr)
Other versions
CA2211324A1 (en
Inventor
Robert A. Murgita
Richard Boismenu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merrimack Pharmaceuticals Inc
Original Assignee
Merrimack Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/377,309 external-priority patent/US5965528A/en
Priority claimed from US08/505,012 external-priority patent/US6331611B1/en
Application filed by Merrimack Pharmaceuticals Inc filed Critical Merrimack Pharmaceuticals Inc
Publication of CA2211324A1 publication Critical patent/CA2211324A1/en
Application granted granted Critical
Publication of CA2211324C publication Critical patent/CA2211324C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4715—Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
CA2211324A 1995-01-24 1996-01-24 Recombinant human alpha-fetoprotein and uses thereof Expired - Lifetime CA2211324C (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US37731695A 1995-01-24 1995-01-24
US37731195A 1995-01-24 1995-01-24
US37731795A 1995-01-24 1995-01-24
US08/377,309 1995-01-24
US08/377,316 1995-01-24
US08/377,311 1995-01-24
US08/377,317 1995-01-24
US08/377,309 US5965528A (en) 1991-09-27 1995-01-24 Recombinant human alph-fetoprotein as an immunosuppressive agent
US08/505,012 1995-07-21
US08/505,012 US6331611B1 (en) 1991-09-27 1995-07-21 Expression and purification of cloned human alpha-fetoprotein
PCT/US1996/000996 WO1996022787A1 (en) 1995-01-24 1996-01-24 Recombinant human alpha-fetoprotein and uses thereof

Publications (2)

Publication Number Publication Date
CA2211324A1 CA2211324A1 (en) 1996-08-01
CA2211324C true CA2211324C (en) 2012-07-10

Family

ID=27541364

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2211324A Expired - Lifetime CA2211324C (en) 1995-01-24 1996-01-24 Recombinant human alpha-fetoprotein and uses thereof

Country Status (7)

Country Link
EP (1) EP0805687A4 (xx)
JP (2) JPH10513347A (xx)
CN (1) CN1150030C (xx)
AU (1) AU700975B2 (xx)
CA (1) CA2211324C (xx)
HK (1) HK1010153A1 (xx)
WO (1) WO1996022787A1 (xx)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965528A (en) 1991-09-27 1999-10-12 Mcgill University Recombinant human alph-fetoprotein as an immunosuppressive agent
US6288034B1 (en) 1995-01-24 2001-09-11 Martinex R & D Inc. Recombinant human alpha-fetoprotein as an immunosuppressive agent
WO1998035981A1 (en) * 1997-02-13 1998-08-20 The Regents Of The University Of California Prevention and treatment of hepatocellular cancer
US7098306B2 (en) 1997-02-13 2006-08-29 The Regents Of The University Of California Method and compositions for treating hepatocellular cancer
US7208576B2 (en) 1999-01-06 2007-04-24 Merrimack Pharmaceuticals, Inc. Non-glycosylated human alpha-fetoprotein, methods of production, and uses thereof
EP1958503A3 (en) * 1999-01-06 2008-11-26 Merrimack Pharmaceuticals, Inc. Expression of secreted human alpha-fetoprotein in transgenic animals
EP1194536B1 (en) * 1999-07-12 2008-12-24 Universite Libre De Bruxelles Non-human genetically modified mammal lacking the alpha-fetoprotein
US7022892B1 (en) 1999-07-12 2006-04-04 Universite Libre De Bruxelles Non-human genetically modified mammal lacking the alpha-fetoprotein
EP1253930A4 (en) * 2000-02-10 2003-05-21 Univ California METHODS AND COMPOSITIONS FOR TREATING HEPATOCELLULAR CANCER
FI118263B (fi) * 2002-10-09 2007-09-14 Timo Kalevi Korpela Kaspaasiaktiivisuutta säätelevät peptidit
US7074561B2 (en) * 2002-10-22 2006-07-11 Biomerieux, Inc. Isothermal amplification based assay for the detection and quantitation of alpha-fetoprotein mRNA
WO2006031611A1 (en) * 2004-09-09 2006-03-23 Serometrix Llc Compositions and methods of using alpha-fetoprotein growth inhibitory peptides
US8932829B2 (en) 2005-07-07 2015-01-13 Elena Dudich Recombinant alpha-fetoprotein and compositions thereof
GB0617564D0 (en) * 2006-09-06 2006-10-18 Ucl Business Plc Peptides and methods
JP2010513518A (ja) * 2006-12-19 2010-04-30 メリマック ファーマシューティカルズ インコーポレーティッド 多発性硬化症治療ためのα‐フェトプロテインおよび免疫調節作用物質の同時投与方法
WO2008113970A2 (en) * 2007-03-16 2008-09-25 Ucl Business Plc Peptides
CN105732795A (zh) * 2016-03-21 2016-07-06 海南医学院 一种获得人类甲胎蛋白的方法
CN112898399A (zh) * 2019-12-03 2021-06-04 香雪生命科学技术（广东）有限公司 源自于afp抗原的短肽
CN113416729B (zh) * 2021-05-18 2022-11-22 遵义医科大学附属医院 一种肝脏靶向调控甲胎蛋白基因的shRNA和cDNA及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5486602A (en) * 1977-10-27 1979-07-10 Hoffmann La Roche Production of purified alpha 1 phetoprotein
JPH025866A (ja) * 1988-06-27 1990-01-10 Kansai Shin Gijutsu Kenkyusho:Kk ヒトアルファフェトプロテインドメインｉ遺伝子、対応プラスミド組換体、対応形質転換体、該ドメインｉの製造法及び製造された該ドメインｉ
IT1226551B (it) * 1988-07-29 1991-01-24 Sclavo Spa Peptide sintetico immunologicamente attivo capace di indurre la produzione di anticorpi con elevata specificita' verso l'alfa- fetoproteina e loro impiego in campo diagnostico
EP0356399A3 (en) * 1988-08-26 1991-03-20 Sandoz Ag Substituted 4-azatricyclo (22.3.1.04.9) octacos-18-ene derivatives, their preparation and pharmaceutical compositions containing them
US5342625A (en) * 1988-09-16 1994-08-30 Sandoz Ltd. Pharmaceutical compositions comprising cyclosporins
US5206153A (en) * 1990-06-27 1993-04-27 Snow Brand Milk Products Co., Ltd. Method of producing human α-fetoprotein and product produced thereby
AU2649592A (en) * 1991-09-25 1993-04-27 Wisconsin Alumni Research Foundation Complexes of anthracycline antibiotics with polyunsaturated fatty acids in lipid emulsions
CA2120131A1 (en) * 1991-09-27 1994-05-11 Robert A. Murgita Expression and purification of cloned human alpha-fetoprotein
DE59509887D1 (de) * 1994-09-26 2002-01-10 Infineon Technologies Ag Koppelanordnung zum optischen aneinanderkoppeln eines oeic-bausteins und optischer fasern

Also Published As

Publication number Publication date
HK1010153A1 (en) 1999-06-17
CN1179106A (zh) 1998-04-15
JPH10513347A (ja) 1998-12-22
AU4903596A (en) 1996-08-14
JP2008073041A (ja) 2008-04-03
EP0805687A4 (en) 2000-05-31
CN1150030C (zh) 2004-05-19
EP0805687A1 (en) 1997-11-12
AU700975B2 (en) 1999-01-14
CA2211324A1 (en) 1996-08-01
WO1996022787A1 (en) 1996-08-01

Similar Documents

Publication Publication Date Title
CA2211324C (en) Recombinant human alpha-fetoprotein and uses thereof
US6974863B2 (en) Antibody for 4-1BB
JP4350301B2 (ja) 可溶性ｍｈｃ複合体とその利用法
US8680057B2 (en) Tribonectins
CA2453965C (en) Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
JP3492999B2 (ja) 脂肪細胞特異的タンパク質の同族体
US20090053254A1 (en) Recombinant human alpha-fetoprotein as an immunosuppressive agent
CA2411470A1 (en) T cell receptor fusions and conjugates and methods of use thereof
JP2005245448A (ja) 活性化ｃｄ４＋ｔ細胞の表層上のレセプターに対するリガンド（ａｃｔ−４−ｌ）
KR100682666B1 (ko) 항혈관형성 단백질 및 이들을 사용하는 방법
EP1284747A2 (en) Compositions and methods for achieving immune suppression
US6774108B2 (en) Recombinant human alpha-fetoprotein as an immunosuppressive agent
CA2448348A1 (en) Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
KR20010015867A (ko) 항-혈관형성 활성을 지니고 있는, 엔도스타틴의 변이체인＂ｅｍ 1＂ 및 이것을 사용하는 방법
US6630445B2 (en) Recombinant alpha-fetoprotein for treating cancers
US6331611B1 (en) Expression and purification of cloned human alpha-fetoprotein
US6627440B1 (en) Recombinant human alpha-fetoprotein as a cell proliferative agent
WO2003031474A2 (en) Cd137 as a proliferation factor for hematopoietic stem cells
AU741557B2 (en) Mammalian secretory peptide-9
US20060063923A1 (en) 4-1BB peptides and methods for use
EP1115863A1 (en) Ucp4
EP1847550A2 (en) Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20160125